The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies

Lenka Pleštilová1,2, Heřman Mann1,2, Lucie Andréš Cerezo1, Ondřej Pecha3, Jiří Vencovský1,2 and Ladislav Šenolt1,2*

Abstract

Introduction: The aim was to evaluate S100A4 protein as a biomarker of disease activity and potential cancer development in patients with myositis.

Methods: Serum levels of S100A4 were determined in 43 dermatomyositis (DM), 39 polymyositis (PM) and 22 cancer associated myositis (CAM) patients as well as in 77 healthy controls. The associations between S100A4 levels, inflammation, disease activity, muscle strength and cancer development were evaluated.

Results: All myositis patients had significantly higher serum levels of S100A4 protein compared to healthy controls (median (IQR): 31.5 (17.4 to 59.5) versus 23.8 (14.5 to 33.7) ng/ml, P <0.05). In patients with PM, serum levels of S100A4 protein were significantly higher than in healthy controls (41.6 (24.2 to 123.1) versus 23.8 (14.5 to 33.7) ng/ml; P <0.001) as well as in patients with DM (26.7 (11.3 to 47.5) ng/ml; P <0.05). The levels of S100A4 were comparable between myositis with and without cancer. In all myositis patients, serum S100A4 levels correlated with MYOsitis disease ACTivity assessment (MYOACT) score (r = 0.34; P = 0.001), constitutional (r = 0.30; P = 0.003), pulmonary (r = 0.43; P = 0.001) and extramuscular disease activity (r = 0.36; P = 0.001), as well as with creatine phosphokinase (r = 0.27; P = 0.015) and lactate dehydrogenase (r = 0.37; P = 0.002) or c-reactive protein (CRP) levels (r = 0.24; P = 0.038). Multiple regression analysis showed significant association between S100A4 serum levels and extramuscular disease activity (β = 0.552; P =0.002) in PM patients and with MYOACT (β = 0.557; P = 0.003) and CRP levels (β = 0.391; P = 0.029) in DM patients.

Conclusions: Circulating levels of S100A4 are elevated in patients with myositis and associate with several disease activity parameters, particularly with extramuscular components. No relation between S100A4 levels and presence of cancer associated myositis was found.

Introduction

Idiopathic inflammatory myopathy is a heterogeneous group of chronic muscle disorders with main subtypes including polymyositis (PM), dermatomyositis (DM), inclusion body myositis and necrotizing myopathy [1]. The diagnosis of myositis is based on the combination of symmetrical muscle weakness accompanied by elevation of circulating muscle enzymes, characteristic electromyography (EMG) and muscle biopsy findings. Extramuscular manifestations of myositis are common and include interstitial lung disease, dysphagia or arthritis, and the presence of distinctive skin rash in patients with DM [2]. An association of idiopathic inflammatory myopathy with malignancy has been documented in a number of studies [3-5]. However, the molecular link explaining the increased risk of cancer in myositis patients is still poorly understood [6,7].

S100A4 protein represents an important member of the S100 family of small calcium-binding proteins [8,9]. Interacting with several target proteins, S100A4 affects a number of activities, accelerating tumorigenesis and invasion of human cancers. At the molecular and cellular level, the cancer-promoting properties of S100A4 are
caused by regulating cell motility, proliferation, apoptosis, and by stimulation of angiogenesis and remodelling of the extracellular matrix [10-14]. The expression of S100A4 protein correlates with the patient's prognosis in breast cancer [15], colorectal cancer [16] and variety of other tumors [10,11]. We and others have recently demonstrated increased expression of S100A4 at local sites of inflammation in several chronic inflammatory and autoimmune diseases [17-21], including muscle tissue from patients with idiopathic inflammatory myopathies [22]. Moreover, we have previously found increased circulating levels of S100A4 in patients with rheumatoid arthritis (RA) in comparison with control individuals and demonstrated a positive correlation between S100A4 and disease activity in RA [23].

Based on these findings we have conducted a study in order to determine the S100A4 serum levels in myositis patients, to evaluate the association between circulating S100A4 and myositis disease activity and to assess a potential role of S100A4 in cancer-associated myositis (CAM).

Methods

Patients and disease activity assessment
A total of 104 patients with myositis (43 with DM, 39 with PM and 22 with CAM) and 77 healthy controls were enrolled in the study. Longitudinal serum samples were available for 11 patients. The interval between the two blood withdrawals was 9 ± 6 months. Myositis patients were recruited from a single centre of the inpatient and outpatient departments of the Institute of Rheumatology in Prague. The diagnosis of DM and PM was based on the Bohan and Peter criteria [24,25]. CAM was defined as cancer occurring within 3 years of the diagnosis of myositis. All individuals gave informed consent to participate and the study was approved by the Ethics Committee of the Institute of Rheumatology in Prague.

Clinical disease activity was evaluated by the disease activity core set measures proposed by International Myositis Assessment & Clinical Studies Group (IMACS): myositis disease activity assessment (MYOACT) and physician global activity using visual analogue scales (VAS), manual muscle testing (MMT) and the health assessment questionnaire (HAQ) [26]. Muscle biopsies performed within one month from the blood withdrawal were available for 13 patients with PM.

Laboratory measurements
Blood samples were collected from all patients and control individuals and stored at −80°C until analysis. Serum S100A4 concentrations were measured by an ELISA kit according to the manufacturer’s protocol (CycLex Co, Ltd, Ina, Nagano, Japan) as demonstrated elsewhere [23]. The analysis was performed using the ELISA reader SUNRISE (Tecan, Salzburg, Austria) at a wavelength of 450 nm.

Serum levels of the muscle-associated enzymes creatine phosphokinase (CK) and lactate dehydrogenase (LD), as well as C-reactive protein (CRP) were measured by routine laboratory techniques. Myositis specific and associated autoantibodies were detected by immunoprecipitation as described elsewhere [27].

Statistical analyses
The data were described as median (IQR) if variables were not normally distributed and as mean (SD) if normally distributed. The Kruskal-Wallis test and corresponding post-hoc analysis and Mann-Whitney test were conducted for comparison between groups. Before analysis of associations among variables, the data were first transformed toward normality. Logarithmic transformation was used because all variables were positively skewed. Pearson's product-moment correlation coefficients were calculated to quantify relationships between disease activity, laboratory markers and S100A4 levels. All correlations were adjusted for age, body mass index, and disease duration using the partial correlation technique. Multiple linear regression analysis was performed to establish whether specific factors were simultaneously associated with the S100A4 as a dependent variable. Covariates included age, sex and disease duration, as well as laboratory markers (CRP, CK and LD) and disease activity measures (MYOACT and its components, extramuscular and muscle disease activity, physician global disease assessment, HAQ and MMT8) were considered as independent variables. The appropriate predictors were chosen using a backward stepwise elimination method. Missing data were excluded using pairwise deletion. P-values <0.05 were considered statistically significant. A correlation coefficient of 0.1 to 0.3 was considered weak, 0.3 to 0.5 was considered moderate and 0.5 to 1.0 was considered strong correlation. The analysis was performed using SPSS 17.0 (SPSS, Chicago, IL, USA) and the graphs were prepared using GraphPad Prism (version 5.00 for Windows, GraphPad Software, San Diego, CA USA, [28]).

Results

Characteristics of patients
The characteristics of myositis patients and healthy controls are summarized in Table 1, and types of cancer in patients with CAM are given in Table 2. A majority of patients with CAM had DM (n = 18). Disease duration ranged from 0 to 18 months from diagnosis. Some patients were treated for specific overlap syndromes,
Table 1 Characteristics and demographic data of patients with idiopathic inflammatory myopathies and healthy controls

|                                      | Dermatomyositis (DM) | Polymyositis (PM) | Cancer-associated myositis (CAM) | Healthy controls (HC) |
|--------------------------------------|----------------------|-------------------|----------------------------------|-----------------------|
| Number                               | 43                   | 39                | 22                              | 77                    |
| Gender, female/male                  | 35/8                 | 25/14             | 20/2                            | 58/19                 |
| Age, years                           | 58 (41 to 63)        | 55 (36 to 60)     | 64 (59 to 70)                   | 45 (31 to 54)         |
| S100A4, ng/ml                        | 26.7 (11.3 to 47.5)  | 41.6 (24.2 to 123.1) | 28.8 (12.6 to 45.4)             | 23.8 (14.5 to 33.7)   |
| S100A4, ng/ml in females             | 26.7 (9.0 to 54.7)   | 54.2 (25.4 to 115.6) | 28.8 (13.0 to 47.5)             | 22.2 (13.6 to 32.1)   |
| S100A4, ng/ml in males               | 30.3 (19.5 to 44.8)  | 41.3 (23.9 to 157.9) | 20.3 (5.5 to 35.0)              | 32.3 (19.9 to 64.6)*  |
| Disease duration, years              | 2.4 (0.4 to 8.3)     | 0.9 (0.5 to 3.2)  | 0.6 (0.2 to 3.6)                 | NA                    |
| Biochemical markers                  |                      |                   |                                  |                       |
| CRP, mg/L                            | 3.3 (1.3 to 9.0)     | 4.7 (2.2 to 26.1)  | 8.0 (3.2 to 26.6)                | NA                    |
| CK, ukat/L                           | 2.6 (1.2 to 9.9)     | 11.6 (2.0 to 29.3) | 10.9 (1.5 to 37.1)              | NA                    |
| LD, ukat/L                           | 4.4 (3.5 to 6.4)     | 7.1 (4.2 to 10.9)  | 5.2 (2.9 to 6.0)                 | NA                    |
| Autoantibodies                       |                      |                   |                                  |                       |
| 6*Mi-2                               |                      |                   |                                  |                       |
| 4*TIF1, 1*TIF1 + U1RNP               | 1* Jo-1 + U1RNP;     |                  | 4*Mi-2                          |                       |
| 2*NXP2                               | 1*Jo-1 + RNAPI + RNAPII |                |                                  |                       |
| 3*PM-Scl                             | 2*PM-Scl             |                   | 1*SAE                           |                       |
| 3*Jo-1                               | 1*PL7                |                   | 3*without known aAbs             |                       |
| 19*without known aAbs                | 1*Ku                 |                   | 1*SRP                           |                       |
|                                       | 1*TIF1 + AMA         |                   | 15*without known aAbs            |                       |
| Clinical features, number            |                      |                   |                                  |                       |
| Muscle weakness                      | 43                   | 39                | 22                              | NA                    |
| Rash                                 | 42                   | 1                 | 16                              | NA                    |
| Mechanic’s hands                     | 18                   | 10                | 8                               | NA                    |
| Raynaud’s phenomenon                 | 9                    | 10                | 3                               | NA                    |
| Arthritis                            | 14                   | 14                | 4                               | NA                    |
| Interstitial lung disease            | 15                   | 22                | 5                               | NA                    |
| Cardiac involvement                  | 10                   | 6                 | 3                               | NA                    |
| Dysphagia                            | 21                   | 15                | 10                              | NA                    |
| Disease activity                     |                      |                   |                                  |                       |
| MYOACT                               | 0.6 (0.15 to 1.5)    | 0.7 (0.2 to 1.3)  | 0.8 (0.5 to 1.8)                 | NA                    |
| Constitutional DA, VAS               | 6 (0 to 18)          | 8 (0 to 24)       | 0 (0 to 28.5)                   | NA                    |
| Cutaneous DA, VAS                    | 15 (0 to 30)         | 0 (0 to 6)        | 28.5 (0 to 52.8)                | NA                    |
| Skeletal DA, VAS                     | 0 (0 to 0)           | 0 (0 to 7)        | 0 (0 to 2)                      | NA                    |
| Gastrointestinal DA, VAS             | 0 (0 to 4)           | 0 (0 to 3)        | 0 (0 to 25.5)                   | NA                    |
| Pulmonary DA, VAS                    | 0 (0 to 7)           | 6.5 (0 to 24.7)   | 0 (0 to 13)                     | NA                    |
| Cardiac DA, VAS                      | 0 (0 to 0)           | 0 (0 to 0)        | 0 (0 to 0)                      | NA                    |
| Extramuscular DA, VAS                | 15 (4 to 34)         | 17 (3.5 to 32.5)  | 20 (11.5 to 54.5)               | NA                    |
| Muscle DA, VAS                       | 10 (3 to 44)         | 32 (14 to 53)     | 37 (5.5 to 68.3)                | NA                    |
including myositis overlap with systemic lupus erythematosus (n = 3) and systemic sclerosis (n = 3). Two patients with immune-mediated necrotizing myopathy (IMNM) were included in the PM subgroup, as they fulfilled the Bohan and Peter classification criteria [24,25]. All patients had proximal muscle weakness. Rash was present in 57%, mechanics hands in 35% and Raynaud’s phenomenon in 21% of patients. Arthritis was diagnosed in 31% and dysphagia in 44% of patients. Myositis-associated interstitial lung disease and cardiac involvement was present in 40% and 18% of patients, respectively. The anti-TIF1 autoantibodies, known to be associated with malignancy, were detected in 17 myositis patients (5 with DM, 1 with PM and 11 with CAM) [29]. Fifteen patients were treatment-naive at the time of assessment. In the 84 patients treated with glucocorticoids at the time of blood withdrawal, the median dose was 15 mg of prednisone or its equivalent per day ranging from 2.5 to 100 mg per day. Twenty-seven patients received methotrexate in addition to glucocorticoids, six patients were treated with cyclosporine A, three with azathioprine and two with hydroxychloroquine (one in monotherapy). Four patients were not treated at the time of blood sample collection, but were on immunosuppressive drugs previously.

Circulating S100A4 is elevated in myositis patients
The levels of serum S100A4 were higher in all myositis patients than in healthy controls (31.5 (17.4 to 59.5) versus 23.8 (14.5 to 33.7) ng/ml, P <0.05). Patients with PM had higher serum levels of S100A4 compared to healthy controls (41.6 (24.2 to 123.1) versus 23.8 (14.5 to 33.7) ng/ml, P <0.001) or to patients with DM (to 26.7 (11.3 to 47.5) ng/ml, P <0.05). There was not a significant difference between patients with DM or CAM and healthy controls (26.7 (11.3 to 47.5) or 28.8 (12.6 to 45.4) versus 23.8 (14.5 to 33.7) ng/ml, both P <0.05) (Figure 1).

The levels of serum S100A4 were higher in healthy male compared to female subjects, but there were no significant sex-related differences in S100A4 levels in myositis patients (Table 1). A weak inverse correlation between S100A4 levels and disease duration was observed in all myositis patients (r = −0.27; P = 0.006). In this context, patients who were treated for longer than 6 months (n = 50) compared with those who were treated for a shorter period of time (n = 54) had lower

| Table 1 Characteristics and demographic data of patients with idiopathic inflammatory myopathies and healthy controls (Continued) |
| --- |
| **Physician’s global disease Assessment, VAS** | 19.5 (4.5 to 43.7) | 30.5 (22.5 to 49.3) | 42.5 (13.5 to 52) | NA |
| **HAQ** | 1.0 (0.3 to 1.9) | 0.9 (0.5 to 1.3) | 1.0 (0.5 to 2.6) | NA |
| **MMT8** | 62 (52 to 74) | 71 (63 to 74.5) | 56 (50.5 to 69.0) | NA |
| **Treatment** | 13.6 (0.9 to 83.6) | 2.0 (0.3 to 72.1) | 1.4 (0.0 to 20.6) | NA |
| **Daily glucocorticoid dosage, mg prednisone equivalent** | 10.0 (2.5 to 40.0) | 25.0 (3.8 to 50.0) | 6.3 (0.0 to 42.5) | NA |
| **Immunosuppressive drugs** | 11*MTX, 3*Plaquinil, 2* AZA, 2*CyA, 23*no immunosuppressive drugs at the time of blood withdrawal, 2*before start of the immunosuppressive treatment | 10*MTX, 1*MTX + AZA, 1*MTX + SAS, 4*CyA, 2*Plaquinil, 1*AZA, 15*no immunosuppressive drugs at the time of blood withdrawal, 5*before start of the immunosuppressive treatment | 4*MTX, 11*no immunosuppressive drugs at the time of blood withdrawal, 7*before start of the immunosuppressive treatment | NA |

Data are presented as number or median (IQR). *S100A4 serum levels in males versus females, P = 0.025. NA, not applicable; CRP, C-reactive protein; CK, creatinine phosphokinase; LD, lactate dehydrogenase; aAbs, autoantibodies; MYOACT, myositis disease activity assessment; DA, disease activity; VAS, visual analogue scale; HAQ, health assessment questionnaire; MMT, manual muscle testing; MTX, methotrexate; AZA, azathioprine; CyA, cyclosporine A; SAS, sulfasalazine.

| Table 2 Types of cancer in patients with cancer-associated myositis |
| --- |
| **Type of cancer** | **Number of patients** |
| Breast cancer | 8 |
| Breast cancer + uterine cancer | 1 |
| Ovarian cancer | 3 |
| Tonsillar cancer | 2 |
| Uterine cancer | 1 |
| Prostate cancer | 1 |
| Hepatic cancer | 1 |
| Colorectal cancer | 1 |
| Sarcoma on the neck | 1 |
| Invasive thymoma | 1 |
| Metastatic cancer of unknown origin | 1 |
| Information missing | 1 |

Table 2 Types of cancer in patients with cancer-associated myositis

Pleštilová et al. Arthritis Research & Therapy 2014, 16:468 Page 4 of 8
http://arthritis-research.com/content/16/5/468
Association between S100A4 levels and myositis disease activity

Increased serum levels of S100A4 were associated with several measures of disease activity in myositis patients overall (Figure 3). Specifically, we found a moderate correlation of S100A4 serum levels with the MYOACT score ($r = 0.34; P = 0.001$), constitutional ($r = 0.30; P = 0.003$), extramuscular ($r = 0.36; P = 0.0001$) and pulmonary disease activity ($r = 0.43; P = 0.0001$), but not with skeletal disease activity ($r = 0.13; P = 0.208$). In addition, there was a weak correlation of S100A4 with CRP ($r = 0.24; P = 0.038$) as well as with CK ($r = 0.27; P = 0.015$) and moderate correlation with LD ($r = 0.37; P = 0.002$) serum levels. On the other side, there was no difference in S100A4 levels between myositis patients with ($n = 32$) and without ($n = 72$) arthritis ($32.3$ (17 to 65) versus $31.5$ (17 to 58) ng/ml, $P = 0.890$).

In patients with PM, S100A4 serum levels moderately correlated with MYOACT ($r = 0.43; P = 0.010$) and with constitutional ($r = 0.43; P = 0.011$), pulmonary ($r = 0.44; P = 0.008$), and extramuscular disease activity ($r = 0.50; P = 0.003$). Additional multiple correlations are given online in Additional file 1: Table S1. There was no correlation of S100A4 serum levels with the degree of endomysial inflammatory infiltrate and/or MHC-I overexpression in the muscle biopsies from patients with PM (data not shown). No association was demonstrated between S100A4 and CK ($r = 0.33; P = 0.064$), LD ($r = 0.36; P = 0.061$), and CRP ($r = 0.26; P = 0.169$) serum levels in PM patients.

In patients with DM, S100A4 serum levels correlated moderately with MYOACT ($r = 0.46; P = 0.004$) and pulmonary disease activity ($r = 0.41; P = 0.011$). Significant correlations were found between S100A4 and CRP levels ($r = 0.38; P = 0.041$), but not CK ($r = 0.09; P = 0.631$) or LD ($r = 0.19; P = 0.365$) serum levels. In addition, we have not observed any significant correlations between S100A4 serum levels and myositis disease activity or laboratory markers in patients with cancer-associated myositis (data not shown).

Multiple regression analysis revealed significant association between S100A4 serum levels, pulmonary disease activity ($\beta = 0.369; P = 0.002$), LD ($\beta = 0.345; P = 0.005$) and severity of dysphagia ($\beta = -0.250; P = 0.033$) in the whole myositis patient group. When analysing the group of PM patients, S100A4 levels were associated only with extramuscular global assessment ($\beta = 0.552; P = 0.002$), while in the group of DM patients, S100A4 levels correlated with MYOACT ($\beta = 0.557; P = 0.003$) and CRP ($\beta = 0.391; P = 0.029$). The group of patients with cancer-associated myositis was too small to perform multiple linear regression analysis. Furthermore, there were no significant bivariate correlations within this group.
Discussion
In this study we demonstrated 1) no relationship between S100A4 and cancer-associated myositis; 2) increased S100A4 serum levels in myositis patients; 3) a relationship between S100A4 and some myositis-specific and myositis-associated autoantibodies; and 4) association between S100A4 levels and several features of myositis disease activity, particularly with extramuscular symptoms.

There is a body of evidence that S100A4 protein is associated with the development of several cancers and particularly with their ability to metastasize [11,12,14]. Given the association of myositis, and dermatomyositis in particular, with increased risk of cancer development [6,7], it may be surprising that we have not observed higher serum levels of S100A4 in patients with cancer-associated myositis and that S100A4 levels were even lower in those with anti-TIF1 autoantibodies, a biomarker that identifies a large proportion of myositis patients with concomitant cancer [30]. We can speculate that either there was S100A4 consumption in cancer tissue or inability to detect enhanced formation of S100A4 multimeric forms that occur during malignancy [18,31].

Although S100A4 protein was initially studied in malignancy [10], there are several reports demonstrating increased amounts of S100A4 in patients with various inflammatory and autoimmune diseases [17,19-21,32]. In addition, we have previously demonstrated that S100A4 is expressed mainly by infiltrating mononuclear cells,
few regenerating muscle fibres and endothelial cells in myositis [22]. In this study, we found increased S100A4 serum levels in all myositis patients and particularly in PM patients compared to those with DM and healthy individuals. Thus, we suggest that S100A4 may either reflect diverse pathological processes that occur in different myositis subtypes and/or that it plays a more important role in PM than in DM.

Furthermore, there was a relationship between circulating S100A4 and the presence of several autoantibodies. We found that the levels of S100A4 are elevated in myositis patients positive for PM-Scl and anti-Jo-1, but not Mi-2 antibodies. Both arthralgia and non-erosive arthritis are common in myositis patients, especially in patients with anti-synthetase autoantibodies such as anti-Jo-1 [33]. As disease activity in patients with RA correlated with S100A4 levels [18,23] and anti-Jo-1-positive patients had increased S100A4 serum levels, we expected that presence of arthritis would contribute to the elevation of S100A4 in myositis patients. However, S100A4 levels were comparable between myositis patients with and without arthritis, which may point to a different pathogenesis of joint involvement in myositis patients compared to those with RA. Thus, it can be hypothesised that in myositis, S100A4 may be associated with systemic activation of the immune system rather than with mechanisms driving arthritis during this debilitating disease.

In our present study, we demonstrated weak to moderate correlation between S100A4 serum levels and various myositis disease-activity measures; on the other side, we found no association between serum S100A4 protein levels and muscle strength or changes in the muscle biopsy. These results may be consistent with the findings showing that muscle fibres do not significantly contribute to S100A4 production and myocytes do not respond to stimulation with S100A4 protein by production of pro-inflammatory cytokines [22,34]. Thus, we can speculate that circulating S100A4 protein may reflect the global disease activity, including extramuscular organ involvement, rather than functional muscle impairment in inflammatory myopathy. In this context, association between S100A4 levels and pulmonary disease activity may be of clinical significance. However, these results should be confirmed in further targeted studies.

**Conclusion**

In summary, we have demonstrated that circulating S100A4 levels are elevated in myositis patients, especially in those with polymyositis, and correlate with several features of myositis disease activity, particularly with extramuscular involvement, but not with the presence of cancer. Further studies evaluating the role of S100A4 in myositis are needed.

**Additional file**

**Additional file 1: Multiple correlations.**

**Abbreviations**

aAb: autoantibodies; AZA: azathioprine; CAM: cancer-associated myositis; CK: creatine phosphokinase; CRP: C-reactive protein; CyA: cyclosporine A; DA: disease activity; DM: dermatomyositis; ELISA: enzyme-linked immunosorbent assay; EMG: electromyography; EQUIV: equivalent; HAQ: health assessment questionnaire; IMACS: International Myositis Assessment & Clinical Studies Group; IQR: interquartile range; LD: lactate dehydrogenase; MMT: manual muscle testing; MTX: methotrexate; MYOACT: Myositis disease activity assessment; NA: not applicable; PM: polymyositis; RA: rheumatoid arthritis; SAS: sulfasalazine; VAS: visual analogue scales.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

All authors were involved in drafting the article or revising it critically for important intellectual content and all approved the final version to be published. LP and LAC performed the laboratory measurements; HM and JV enrolled patients in the study and provided clinical data for the patients; OP participated in study design, statistical analysis and interpretation of data; LP, LS and JV designed the study, analysed data and wrote the manuscript.

**Acknowledgements**

We thank Associate Professor Josef Zámečník from the Department of Pathology and Molecular Medicine, Second Medical Faculty and University Hospital Motol, Charles University in Prague, Czech Republic for assessing muscle biopsies. We thank Dr Zoe E Betteridge and Professor Neil J McHugh from Royal National Hospital for Rheumatic Diseases, NHS Foundation Trust, Upper Borough Walls, Bath, for detecting myositis-specific and myositis-associated autoantibodies in patients’ sera by radioimmunoprecipitation. This study was supported by the Ministry of Health of the Czech Republic (MCHCR) for conceptual development of a research organization (OZSP/28), IGA MCHCR (NT 13698-4), INIA project BTCure (15114-2) and Research Project 5W (250/31).

**Authors**

1 Institute of Rheumatology, 12850 Prague, Czech Republic. 2 Department of Rheumatology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. 3 Technology Centre of the Academy of Sciences, Prague, Czech Republic.

**Received**: 17 April 2014 **Accepted**: 14 October 2014

**Published online**: 31 October 2014

**References**

1. Dalakas MC, Hohlfeld R: Polymyositis and dermatomyositis. Lancet 2003, 362:971–982.
2. Spiera R, Kagen L: Extramuscular manifestations in idiopathic inflammatory myopathies. Curr Opin Rheumatol 1998, 10:556–561.
3. Hill CL, Zhang Y, Sigurjónsson B, Pukkanla E, Mellemkjær L, Airo A, Evans SR, Felson DT: Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001, 357:96–100.
4. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G: Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001, 134:1087–1095.
5. Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT: Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 2010, 12:R70.
6. Zampieri S, Valente M, Adamo N, Biral D, Ghirardello A, Rampulla ME, Vecchiato M, Sarzo G, Corbican S, Kern H, Carraro U, Bassetto F, Mergillano S, Doria A: Polymyositis, dermatomyositis and malignancy: a further intriguing link. Autoimmun Rev 2010, 9:449–453.
7. Zahri ZA, Baer AN: Malignancy in myositis. Curr Rheumatol Rep 2011, 13:208–215.
8. Ebrelidze A, Tulchinsky E, Grigorian M, Afanasyeva M, Senin V, Revazova E, Lukandin E: Isolation and characterization of a gene specifically
expressed in different metastatic cells and whose deduced protein product has a high degree of homology to a Ca2+−binding protein family. Genes Dev 1989, 3:1086–1093.

9. Donato R, S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001, 33:637–648.

10. Boye K, Maelandsmo GM: S100A4 and metastasis: a small actor playing many roles. Am J Pathol 2010, 176:528–535.

11. Helfman DM, Kim EJ, Lukandin E, Grigorian M: The metastasis associated protein S100A4 role in tumour progression and metastasis. Br J Cancer 2005, 92:1953–1958.

12. Klingelhofer J, Grum-Schwensen B, Beck MK, Knudsen RS, Grigorian M, Lukandin E, Ambartsumian N: Anti-S100A4 antibody suppresses metastasis formation by blocking stroma cell invasion. Neoplasia 2011, 14:1260–1268.

13. Lukandin E, Sleeman JP: Building the niche: the role of the S100 proteins in metastatic growth. Semin Cancer Biol 2012, 22:16–22.

14. Wang L, Wang X, Liang Y, Xiao X, Chen Q: S100A4 promotes invasion and angiogenesis in breast cancer MDA-MB-231 cells by upregulating matrix metalloproteinase-9. Acta Biochim Pol 2012, 59:593–598.

15. Rudland PS, Platt-Higgins A, Renshaw C, West CR, Winstanley JH, Robertson L, Baracclaugh R: Prognostic significance of the metastasis-inducing protein S100A4 (p90k) in human breast cancer. Cancer Res 2000, 60:1595–1603.

16. Takenaga K, Nakashita H, Wada K, Suzumi M, Matsuzaki M, Matsuura A, Endo H: Increased expression of S100A4, a metastasis-associated gene, in human colorectal adenocarcinoma. Clin Cancer Res 1997, 3:2309–2316.

17. Grigorian M, Ambartsumian N, Lukandin E: Metastasis-inducing S100A4 protein: implication in non-malignant human pathologies. Curr Mol Med 2008, 8:492–496.

18. Klingelhofer J, Senolt L, Baslund B, Nielsen GH, Skibshøj J, Pavelka K, Neidhart M, Gay S, Grigorian M, Vencovsky J, Senolt L: Up-regulation of metastasis-promoting S100A4 (Mts-1) in rheumatoid arthritis: putative involvement in the pathogenesis of rheumatoid arthritis. Rheitis 2007, 56:779–789.

19. Zibert JR, Skov L, Thysen JP, Jacobsen GK, Grigorian M: Significance of the S100A4 protein in psoriasis. J Invest Dermatol 2010, 130:150–160.

20. Boornshere CS, Chamberlain A, Kendall P, Afshar-Sharif AR, Huang H, Washington MK, Lawson WE, Thomas JW, Blackwell TS, Bhoomrk NA: Autoimmune pancreatitis results from loss of TGFbeta signalling in S100A4-positive dendritic cells. Gut 2009, 58:1267–1274.

21. Cunningham MF, Docherty NG, Burke JP, O’Connell PR: S100A4 expression is increased in stricture fibroblasts from patients with fistulising Crohn’s disease and promotes intestinal fibroblast migration. Am J Physiol Gastrointest Liver Physiol 2010, 299:G547–G566.

22. Cerezo LA, Kumagawa K, Mann H, Tomcik M, Zámečník J, Lukandin E, Neidhart M, Gay S, Grigorian M, Vencovsky J, Senolt L: The metastasis promoting protein S100A4 is increased in idiopathic inflammatory myopathies. Rheumatology (Oxford) 2011, 50:1766–1772.

23. Odlejóvková L, Grigorian M, Hulejová H, Vencovsky J, Pavelka K, Klingelhofer J, Gay S, Neidhart M, Brabcová H, Suchý D, Odlejóvková L, Grigorian M, Hulejová H, Vencovsky J, Pavelka K, Klingelhofer J, Gay S, Neidhart M, Brabcová H, Suchý D, Senolt L: Metastasis-inducing S100A4 protein is associated with the disease activity of rheumatoid arthritis. Rheumatology (Oxford) 2009, 48:1590–1594.

24. Bohan A, Peter JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975, 292:344–347.

25. Bohan A, Peter JB: Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975, 292:403–407.

26. Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, Oddis C, Pilkington C, Plotz P, Scott D, Vencovsky J, Cooper R, Rider L, Miller F, International Myositis and Clinical Studies Group (IMACS): International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004, 43:49–54.

27. Betteridge Z, Gunawardena H, North J, Slinn J, Mchugh N: Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia. Rheumatology (Oxford) 2007, 46:1005–1008.

28. GraphPad Software [http://www.graphpad.com]